$1.78+0.03 (+1.71%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Lexicon Pharmaceuticals (LXRX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
55 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~369.2%/yr (FY21→FY25), net margin −34.9%. Worth your attention in FY25: Share count (+149.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
144.4
no value for 1 of 5 yearsCAGR —
Net income ($M)—
−50.3
no value for 1 of 5 yearsCAGR —
Free cash flow ($M)▲62.3%
−67.9
FY21→FY25CAGR —
Diluted EPS—
−0.14
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+149.3%
145.7mn → 363.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$0.0K
−100.0% YoY in FY25 · 0.0% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-35¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -34.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 133,184.0 | 144,450.0 | —A | 1,204.0 | 139.0 | 298.0 | — | — |
Cost of revenue | 427.0 | 274.0 | —A | 85.0 | 0.0 | 0.0 | — | — |
Gross profit | 132,757.0 | —B | —A | 1,119.0 | —C | —C | — | — |
Research & development | 57,717.0 | 61,121.0 | —A | 58,887.0 | 52,816.0 | 55,046.0 | — | — |
Selling, general & admin | 45,544.0 | 45,658.0 | —A | 113,982.0 | 48,083.0 | 32,342.0 | — | — |
Total operating expenses | 201,975.0 | 205,493.0 | —A | 172,869.0 | 100,899.0 | 87,388.0 | — | — |
Operating incomefeeds ROC rank | −56,812.0 | −48,911.0 | —A | −171,750.0 | −100,760.0 | −87,090.0 | — | — |
Other income, net | −9,451.0 | −5,341.0 | —A | −5,369.0 | −2,780.0 | 134.0 | — | — |
Pretax income | −66,263.0 | −54,252.0 | —A | −177,119.0 | −103,540.0 | −86,956.0 | — | — |
Income tax | — | — | —A | — | — | — | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −62,352.0 | −50,341.0 | —A | −177,119.0 | −101,944.0 | −87,758.0 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.14 | −0.14 | —A | −0.80 | −0.62 | −0.60 | — | — |
Diluted shares (mn) | 444.96 | 363.05 | —A | 221.13 | 165.73 | 145.65 | — | — |
| Margins | ||||||||
Gross margin99th pct in Healthcare | 99.7% | —B | —A | 92.9% | —C | —C | — | — |
Operating margin | −42.7% | −33.9% | —A | −14265.0% | −72489.2% | −29224.8% | — | — |
Net margin17th pct in Healthcare | −46.8% | −34.9% | —A | −14710.9% | −73341.0% | −29449.0% | — | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld by our checks.B Withheld: this year's gross margin is not on the same cost basis as the earlier years.C Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Lexicon Pharmaceuticals' net income?
Lexicon Pharmaceuticals reported net income of −$50.3M in fiscal 2025, a net margin of −34.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

